Free tool
FAERS Monitor: Roxybond
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209777 or its brand name (Roxybond, Oxycodone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
84,853
Serious
74,866
88% of reports
Hospitalization
14,871
Death reported
30,340
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug dependence24,868
- pain18,004
- overdose16,632
- emotional distress14,587
- death13,667
- toxicity to various agents12,576
- drug withdrawal syndrome9,399
- drug ineffective3,854
- fatigue3,790
- drug abuse3,468
- nausea3,359
- off label use2,744
- dyspnoea2,641
- rash2,641
- anxiety2,626
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 13 |
| 2005 | 14 |
| 2006 | 32 |
| 2007 | 54 |
| 2008 | 96 |
| 2009 | 84 |
| 2010 | 112 |
| 2011 | 144 |
| 2012 | 437 |
| 2013 | 596 |
| 2014 | 541 |
| 2015 | 724 |
| 2016 | 2,142 |
| 2017 | 3,956 |
| 2018 | 24,810 |
| 2019 | 2,873 |
| 2020 | 4,715 |
| 2021 | 12,661 |
| 2022 | 15,115 |
| 2023 | 4,326 |
| 2024 | 4,016 |
| 2025 | 4,270 |
| 2026 | 3,122 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,969,306 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug dependenceSignal | 24,868 | 45.2 | 44.6 | 914,880 |
| emotional distressSignal | 14,587 | 33.8 | 33.3 | 410,953 |
| drug withdrawal syndromeSignal | 9,399 | 29.6 | 29.0 | 232,993 |
| overdoseSignal | 16,632 | 20.6 | 20.3 | 289,583 |
| toxicity to various agentsSignal | 12,576 | 19.9 | 19.6 | 210,507 |
| drug abuseSignal | 3,468 | 10.7 | 10.4 | 29,439 |
| painSignal | 18,004 | 7.5 | 7.4 | 100,595 |
| deathSignal | 13,667 | 4.0 | 3.9 | 31,283 |
| anxietySignal | 2,626 | 2.3 | 2.2 | 1,935 |
| rash | 2,641 | 1.5 | 1.4 | 454 |
| fatigue | 3,790 | 1.2 | 1.2 | 140 |
| dyspnoea | 2,641 | 1.2 | 1.1 | 57 |
| nausea | 3,359 | 1.1 | 1.0 | 9 |
| off label use | 2,744 | 0.8 | 0.7 | 184 |
| drug ineffective | 3,854 | 0.7 | 0.7 | 431 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.